logo
Study finds strong link between illegal drug use and homelessness — and unmet need for treatment

Study finds strong link between illegal drug use and homelessness — and unmet need for treatment

Yahoo27-02-2025
Illegal drug use is deeply intertwined with homelessness, both increasing the risk of losing housing and arising or worsening when people find themselves on the streets, a new study has found. But it also found that a large majority of people living on the streets are not drug users.
The study, published in the medical journal JAMA by the Benioff Homeless and Housing Initiative at UC San Francisco, gives a complex statistical picture of a topic that has been fraught by conflicting narratives. Against a public perception that drug use is endemic to homeless camps, service providers and advocates see an exaggerated reaction to open drug use on the street that stigmatizes the majority of homeless people who do not use drugs.
The Benioff study supports some elements of both viewpoints. Contrary to common perception, only about 37% of homeless people were using illicit drugs regularly, and 25% said they had never used drugs. But drug use is far more prevalent among homeless people than in the general population. Just over 65% reported having regular used at some point in their lives, and 27% had started after becoming homeless.
Another twist: 35% said their drug use had decreased after they became homeless. Some were parents worried about losing custody of their children. Others had "just reached that point," said lead author and Benioff director Margot Kushel.
That finding highlighted the need for better treatment options, Kushel said. Many told interviewers that had already cut back and would like help to cut back more.
"One of the most poignant findings was that 1 in 5 told us they are actively seeking treatment and couldn't get it," Kushel said in an interview.
In-depth interviews illustrated their frustration, Kushel said, with respondents saying, "I'm showing up where they tell me to show up, calling where they tell me to call," only to be turned away.
Only 7% of those with any lifetime use said they were receiving treatment.
"Its hard to get treatment," Kushel said. "It shouldn't be. You shouldn't scrounge to save money to go somewhere and be told you'll be put on a waiting list. That should not happen, but it does."
Housing is the solution, Kushel said, but until enough of it is available, there is a need to bring more resources to the street, such as methadone or other medications that treat opioid addiction.
Kushel also urged increased access to residential treatment as long as it could lead to housing and that those who relapse in treatment — "very common and part of the natural history of substance use disorders" — would not be returned to homelessness.
The report, Illicit Substance Use and Treatment Access Among Adults Experiencing Homelessness, is one of a series of reports based on Benioff's 2023 Statewide Study of People experiencing homelessness. The largest representative sample of homelessness since 1990s, it consisted of 3,200 questionnaires and 365 in-depth interviews.
Prior Benioff reports based on the survey have covered intimate partner violence and pathways to homelessness.
Unlike the 1990s survey, which included only people using homeless services, Benioff canvassed both shelters and encampments, noting that homeless patterns had changed, with a higher proportion unsheltered, and drug preferences in the general population had shifted from cocaine to methamphetamine and fentanyl.
The new report found that methamphetamine was, by far, the most used drug on the street.
"People are telling us that it helps them survive," Kushel said. "It keeps them awake and alert. They are using it either because they are traumatized, they have been assaulted, they are afraid or depressed, using it as coping to make it all go away."
Only about 10% of respondents said they were regularly using opioids, most mixing them with methamphetamine. But even intermittent use, or unwitting use through contamination, poses a high risk of death. Just under 20% had experienced an overdose in their lifetimes and 10% in their current episode of homelessness.
About a quarter reported having naloxone, a medicine that reverses an opioid overdose, but Kushel said it should be in the hands of every opioid user and everyone around them.
"What we've heard from a lot of people is, 'I've seen an overdose,'" she said. "You can't often wait for a first responder."
Despite the high lifetime use of cocaine, at 58%, only 3% said they were currently using it.
"Like a lot of things we talk about in medicine, some things get worse, some things get better, some things stay the same," Kushel said.
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
This story originally appeared in Los Angeles Times.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tibremciclib for Advanced Breast Cancer: Is It Worth It?
Tibremciclib for Advanced Breast Cancer: Is It Worth It?

Medscape

timean hour ago

  • Medscape

Tibremciclib for Advanced Breast Cancer: Is It Worth It?

Adding the novel CDK4/6 inhibitor tibremciclib (Betta Pharmaceuticals) to second-line fulvestrant significantly extended progression-free survival (PFS) in patients with HR-positive/HER2-negative advanced breast cancer, but with the tradeoff of increased toxicity, new data suggest. Compared with fulvestrant alone, the combination prolonged median PFS for these patients by 11 months, according to results from the phase 3 TIFFANY trial. However, similar to existing CDK4/6 inhibitors, the tibremciclib-fulvestrant combination added to treatment side effects — including substantially higher rates of diarrhea, hematologic toxicities, and hypokalemia. The authors of the analysis, published in JAMA Oncology , described the toxicities as "manageable," emphasizing that few patients stopped treatment because of them. Study author Xichun Hu, MD, of Fudan University Shanghai Cancer Center, told Medscape Medical News that tibremciclib compares favorably with other CDK4/6 inhibitors in terms of dose reduction and discontinuation rates. However, Hu noted, that's based on cross-trial comparisons, which have to be interpreted with caution. Kathy Miller, MD, who was not involved in the trial, had a similar take. 'Toxicity actually looks similar to ribociclib and palbociclib, with primarily myelosuppression and little non-heme toxicity,' Miller, of the Melvin and Bren Simon Comprehensive Cancer Center at Indiana University, told Medscape Medical News. Tibremciclib plus fulvestrant was recently approved in China for HR-positive/HER2-negative advanced breast cancer following results from the trial, but the combination has yet to be approved in the US. The Benefits vs the Risks In the trial, Hu and colleagues studied the safety and efficacy of the new agent among patients from 69 centers in China who had experienced progression while on endocrine therapy and had received no more than one line of chemotherapy. A total of 274 patients were randomized (2:1) to receive either tibremciclib (400 mg orally, once daily) or placebo plus fulvestrant until disease progression, death, or treatment discontinuation over a median follow-up of 13 months. Eighty patients (43.5%) in the tibremciclib arm and 64 (71.1%) in the placebo arm experienced a PFS event (disease progression or death). Tibremciclib plus fulvestrant significantly improved PFS to 16.5 months versus 5.6 months with fulvestrant alone, reducing the risk of progression by 63% (hazard ratio [HR], 0.37; P < .001). As for safety, adverse events were higher in the treatment arm. The most common treatment-emergent adverse events were diarrhea (79.3% in the tibremciclib arm vs 13.3% in placebo arm), neutropenia (75.5% vs 15.6%), leukopenia (73.9% vs 16.7%), and anemia (69% vs 21.1%). Nausea and vomiting were also more common with tibremciclib, at 37% and 40.2%, respectively — versus 18.9% and 11.1% in the placebo group. Most often, those adverse events were grade 1 or 2. However, 50.5% of patients in the tibremciclib group had a grade 3 or higher treatment-emergent adverse event, versus 21.1% in the placebo group. The most common were neutropenia (15.2% vs 5.6%), anemia (12.0% vs 4.4%), and hypokalemia (12% vs 0%). Hypokalemia was often due to diarrhea and was managed with electrolyte monitoring and potassium supplementation, Hu said. One-third of patients in the tibremciclib arm developed hypertriglyceridemia (5.4% grade 3 or higher) — a rate higher than that seen with other CDK4/6 inhibitors. Cases were managed with lipid-lowering agents such as atorvastatin. More patients on tibremciclib experienced dosing interruptions due to adverse events (54% vs 23%), and dose reductions were also more common with the combination therapy (18.5% vs 4.4%). However, only four patients (all in the tibremciclib arm) discontinued treatment due to side effects. Overall, the adverse event profile of tibremciclib lines up with that of other CDK4/6 inhibitors and comes with better PFS, Hu said, noting that "the benefit-risk balance of tibremciclib plus fulvestrant appears highly favorable." In TIFFANY, the authors note d that cases of neutropenia and leukopenia were numerically lower than in trials of abemaciclib, dalpiciclib, and palbociclib plus fulvestrant. According to Hu, tibremciclib is structurally different from other drugs in its class, with a greater selectivity for CDK4 and less inhibition of CDK6 and CDK9, which may reduce the incidence of neutropenia as well as severe diarrhea. Plus, the PFS improvement seen in TIFFANY was greater, Hu said. Pa lbociclib in PALOMA-3 showed a median PFS of 9.5 months vs 4.6 months for fulvestrant alone (HR, 0.46); abemaciclib in MONARCH led to a PFS of 11.5 months vs 5.6 months (HR, 0.38, a Chinese population); and dalpiciclib in DAWNA-1 achieved 16.6 months vs 7.2 months (HR, 0.50, also in Chinese patients). While these are cross-trial comparisons, it's still unclear exactly how tibremciclib stacks up against other drugs in its class (including its impact on overall survival). The authors also caution that, because the trial exclusively enrolled Chinese patients without prior CDK4/6 inhibitor exposure, the findings may not be generalizable to broader populations, particularly in regions like North America and Europe. Miller pointed to the generalizability question as well, noting that fulvestrant monotherapy is typically not the standard of care in the US and other Western countries. 'This [study] joins a long list of second-line endocrine studies that show drug activity but don't compare to standard of care and don't really tell us how to best use the drug,' Miller said.

AI-powered brain implant restores speech in paralysis patient after 18 years
AI-powered brain implant restores speech in paralysis patient after 18 years

Yahoo

time2 hours ago

  • Yahoo

AI-powered brain implant restores speech in paralysis patient after 18 years

Eighteen years after a brainstem stroke left her with near-total paralysis, Ann Johnson heard her voice again, thanks to a brain-computer interface (BCI) that decodes speech directly from brain activity. Johnson, then 30, was a high school teacher and coach in Saskatchewan, Canada, when the 2005 stroke caused locked-in syndrome, a rare condition in which a person remains conscious but unable to speak or move. Since then, she has communicated using an eye-tracking system at just 14 words per minute, a far from natural conversational speed of about 160 words per minute. In 2022, she became the third participant in a clinical trial led by researchers at the University of California, Berkeley, and UC San Francisco aimed at restoring speech for people with severe paralysis. The team used a neuroprosthesis that records signals from the speech motor cortex, bypassing damaged neural pathways to produce audible words. Turning thought into voice The device relies on an implant placed over the brain's speech production area. When Johnson attempts to speak, the implant detects neural activity and sends the signals to a connected computer. An AI decoder then translates these signals into text, speech, or facial animation on a digital avatar. Originally, the system used sequence-to-sequence AI models that required an entire sentence before producing output, creating an eight-second delay. In March 2025, the team reported in Nature Neuroscience that they had switched to a streaming architecture, allowing near-real-time translation with just a one-second delay. To personalize the experience, researchers recreated Johnson's voice from a recording of her 2004 wedding speech. She also selected an avatar to match her appearance, which can mimic facial expressions such as smiling or frowning. Engineering for everyday use Lead researchers Assistant Professor of Electrical Engineering and Computer Sciences Gopala Anumanchipalli (UC Berkeley), neurosurgeon Edward Chang (UCSF), and Berkeley Ph.D. student Kaylo Littlejohn say the goal is to make neuroprostheses 'plug-and-play,' turning them from experimental systems into standard clinical tools. Future improvements could include wireless implants, eliminating the need for direct computer connections, and photorealistic avatars for more natural interactions. The team envisions digital 'clones' that replicate not just a user's voice but also their conversational style and visual cues. The breakthrough could help a relatively small but highly vulnerable population, including people who lose the ability to speak due to stroke, ALS, or injury, reclaim faster, more natural communication. Researchers emphasize that the system only works when the participant intentionally tries to speak, preserving user agency and privacy. For Johnson, the trial was life-changing. 'I want patients to see me and to know their lives are not over now,' she said in a statement to UCSF. She hopes to one day work as a counselor in a rehabilitation center, using a neuroprosthesis to talk with clients. With latency down to about a second and ongoing advances in AI modeling, the researchers believe practical, real-time speech restoration could arrive within just a few years, reshaping how technology gives voice to those who have lost their own. Solve the daily Crossword

Popular weight-loss drugs linked to sudden vision loss, research suggests
Popular weight-loss drugs linked to sudden vision loss, research suggests

Yahoo

time6 hours ago

  • Yahoo

Popular weight-loss drugs linked to sudden vision loss, research suggests

New research has discovered certain weight-loss medications could be associated with an increased risk of serious eye conditions, and even vision loss. Two studies, published in JAMA, analyzed how semaglutide and tirzepatide — which include popular drugs like Ozempic, Wegovy, Mounjaro and Zepbound — impacted eye health in Americans with type 2 diabetes over a two-year period. One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN) – a rare eye condition that can lead to sudden vision loss due to lack of blood flow – in association with semaglutide and tirzepatide. Popular Weight-loss Medication Could Relieve Painful Arthritis Symptoms, Doctors Report Out of more than 159,000 study participants with type 2 diabetes, 35 developed NAION, compared to 19 people in the comparison group. The Ohio-based researchers also noted an increased risk of developing "other optic nerve disorders," identified in 93 patients. Read On The Fox News App Although the second study did not observe a "statistically significant difference" in NAION in GLP-1 drug users, there was a small increase in diabetic retinopathy, an eye disease that can damage the retina. Diabetic Patients Taking Glp-1s May Face Increased Risk Of Eye Disease, Study Suggests While individuals with type 2 diabetes on GLP-1s showed a modestly increased risk of diabetic retinopathy, the researchers concluded that fewer patients experienced sight-threatening complications from the disease. "These findings suggest that all patients with type 2 diabetes treated with GLP-1 RAs, regardless of preexisting diabetic retinopathy, should be regularly screened and monitored for potential complications," the study authors concluded. Sue Decotiis, M.D., a medical weight loss doctor in New York City, said she believes more studies are required to confirm the association between these drugs and vision loss, as these studies report some conflicting results. "NAION is a rare condition of the optic nerve that, although serious, has not really been shown to be increased by these studies," Decotiis, who was not involved in the research, told Fox News Digital. "We need more studies for certain." Diabetic patients already face a high incidence of eye disease related to blood flow and nerve damage, the expert noted. "Eye complications are often directly related to the degree or lack thereof of diabetes control." Click Here To Sign Up For Our Health Newsletter In most cases, GLP-1 drugs reduce the severity of type 2 diabetes, therefore reducing the incidence of eye diseases, Decotiis noted. These drugs have also been shown to reduce the risk of cardiovascular disease, like hypertension, and to improve circulation, which can improve eye health. For diabetics who are starting a GLP-1, Decotiis recommends having an exam done by an ophthalmologist and scheduling follow-up exams throughout treatment. "We should take precaution with methodical ophthalmic care for diabetics on these drugs," Decotiis said. "However, let's not throw the baby out with the bath water." For more Health articles, visit Novo Nordisk, maker of Ozempic and Wegovy, provided the following statement when contacted by Fox News Digital. "Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously. NAION is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and Wegovy) as per the approved labels in the U.S." "Novo Nordisk, on its part, has conducted an analysis across randomized controlled clinical trials with GLP-1 receptor agonists, including a blinded ophthalmologist evaluation to confirm NAION diagnoses. Our current assessment is that these data do not suggest a causal relationship between GLP-1 RA use and NAION events."Original article source: Popular weight-loss drugs linked to sudden vision loss, research suggests Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store